Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PVSP on X - "Everything is Falling into Place" !!!
Pervasip Corp
@PervasipC
·
$PVSP Everything is falling into place
https://twitter.com/search?q=%24PVSP&src=cashtag_click
Today the MJ Sector got Great Long Awaited News and Many Companies Enjoyed a Great Day in the Market. $PVSP traded less than 2,900.00$ Can Management Bring this Back to Life... .0004 is Rough...2 Billion Share Reduction would Help?? U Approved it 07/2022... @PervasipC https://t.co/I2N2vk9s9L pic.twitter.com/aubTq0s4zg
— Urocka (@UrockaLife) May 1, 2024
Pot Stocks Surge on Report DEA Is Moving to Reclassify Marijuana
Carmen Reinicke, Bloomberg News
(Bloomberg) -- Shares of cannabis-related companies jumped Tuesday after the US Drug Enforcement Administration moved to reclassify marijuana to a less dangerous drug category in what would be a historic shift for the industry.
Tilray Brands Inc. jumped 40%, while Canopy Growth Corp. gained 79%. The MJ PurePlay 100 Index, which tracks the industry globally, rose 22%, the most since October 2022. Meanwhile, the AdvisorShares Pure US Cannabis ETF surged 25% and was halted for volatility in intraday trading.
Investors have been long awaiting DEA action on the reclassification of marijuana, which has been grouped with drugs such as LSD and heroin. Moving the substance to a different group would remove additional taxes that cannabis companies have to pay — a major overhang for the industry. The agency has been reviewing the classification for marijuana since September after a nudge from the Biden administration.
“There’s been a lot of rumors coming out in the last few days but this looks official,” said Dan Ahrens, managing director of Advisorshares Investments LLC, adding that this move from the DEA could start a domino effect. “I think it makes it easier for the House and Senate to act on SAFER Banking.”
The SAFER Banking Act would make banking and financial services more accessible for the industry.
Cannabis industry stocks have risen this year and even outperformed the S&P 500 Index as investors bought back into the beaten down names in anticipation of the DEA action. Still, pot stocks are trading at steep discounts to the highs hit a few years ago at the start of the cannabis boom.
Read more: WEED, MJ Beating S&P 500 as Cannabis-Reform Hopes Mount
In addition to removing extra taxes cannabis companies have to pay and therefore boosting cash flow, changing the classification could also help bring institutional investment to the industry, Jefferies analyst Owen Bennett wrote in a Tuesday note.
“The major reason current multiples are depressed is lack of institutional ownership,” Bennett wrote, adding that this is due to a combination of factors including major exchanges not listing cannabis stocks.
Reclassification could also prompt more states in the US to legalize marijuana, help destigmatize use and make it easier for the substance to be studied, according to the Jefferies note.
The move “would hugely improve the prospects of full federal legalization within the next 5 years, with a critical piece of this move making it easier to study cannabis and thereby fill in the data gaps where there may be concerns around its widespread use among the population,” said Bennett.
Of course, it’s not clear when the final word on the change could come from the DEA. In his note, Bennett said a rule could be published this week, while Needham analyst Matthew McGinley expects a scheduling announcement in the coming months, he wrote in a note.
“If enacted, rescheduling would be a significant federal reform and the most substantial incremental policy change regarding cannabis at the federal level in a century,” said McGinley.
The government is shifting Cannabis from Schedule I to Schedule III
Attorney general moves to reclassify marijuana as lower-risk drug, officials say
By Michael Scherer, Tyler Pager, Dan Diamond and David Ovalle
Updated April 30, 2024 at 2:45 p.m. EDT|Published April 30, 2024 at 1:55 p.m. EDT
The White House Office of Management and Budget must review the proposal from the Drug Enforcement Administration to reclassify marijuana. (Arin Yoon/for The Washington Post)
Attorney General Merrick Garland on Tuesday will recommend loosening restrictions on marijuana in what would be a historic shift in federal drug policy, according to multiple people familiar with the matter.
The measure, if enacted, would not instantly legalize marijuana at the federal level but could broaden access to the drug for medicinal use and boost cannabis industries in states where it is legal. The move may also prove to be a political win for President Biden, who is campaigning for reelection and has sought to ameliorate racial and criminal justice inequities wrought by the nation’s long war on drugs.
The Justice Department was scheduled to submit the formal recommendation to the White House on Tuesday. It follows the Drug Enforcement Administration’s approval of the Department of Health and Human Services recommendation that marijuana be reclassified.
The White House Office of Management and Budget must review the measure, according to the people familiar with the matter, who spoke on the condition of anonymity to discuss internal administrative matters. The measure, if accepted, would not go into effect for months until the public has a chance to comment.
The DEA’s approval was first reported Tuesday by the Associated Press. The DEA, the Justice Department and the White House declined to comment.
For more than five decades, marijuana has been classified as a Schedule I controlled substance with a high potential for abuse and no accepted medical use. Under the DEA’s proposed change, marijuana would go to the less-risky Schedule III — in the same tier as prescription drugs such as ketamine, anabolic steroids and testosterone.
The historic policy shift comes as marijuana is easier than ever to obtain and has become an industry worth billions in the United States. Thirty-eight states and D.C. have legalized medical marijuana programs, and 24 have approved recreational marijuana.
Biden administration plans to reclassify marijuana, easing restrictions nationwide
Cannabis is currently classified along with drugs like heroin and LSD. The DEA is expected to reschedule it into a category that includes Tylenol and steroids.
Since 1971, marijuana has been in the same category as heroin, methamphetamines and LSD.
April 30, 2024, 1:30 PM EDT / Updated April 30, 2024, 2:05 PM EDT
By Julie Tsirkin and Monica Alba
WASHINGTON — The Biden administration will take a historic step toward easing federal restrictions on cannabis, with plans to announce an interim rule soon reclassifying the drug for the first time since the Controlled Substances Act was enacted more than 50 years ago, four sources with knowledge of the decision tell NBC News.
The Drug Enforcement Administration is expected to approve an opinion by the Department of Health and Human Services that marijuana should be reclassified from the most strict Schedule I to the less stringent Schedule III, marking the first time that the U.S. government would acknowledge its potential medical benefits and begin studying them in earnest.
The Justice Department "continues to work on this rule," a Biden administration official said. "We have no further comment at this time."
What rescheduling means
Since 1971, marijuana has been in the same category as heroin, methamphetamines and LSD. Each substance under the Schedule I classification is defined as a drug with no accepted medical use and a high potential for abuse. Schedule III substances include Tylenol with codeine, steroids and testosterone.
By rescheduling cannabis, the drug would now be studied and researched to identify concrete medical benefits, opening the door for pharmaceutical companies to get involved with the sale and distribution of medical marijuana in states where it is legal.
For the $34 billion cannabis industry, the move would also eliminate significant tax burdens for businesses in states where the drug is legal, notably getting rid of the Internal Revenue Services code Section 280E which currently prohibits legal cannabis companies from deducting what would otherwise be ordinary business expenses.
The Department of Justice’s rescheduling decision could also help shrink the black market which has thrived despite legalization in states like New York and California and has undercut legal markets that are fiercely regulated and highly taxed.
Years in the making
President Joe Biden directed the Department of Health and Human Services in October of 2022 to review marijuana’s classification. Federal scientists concluded that there is credible evidence that cannabis provides medical benefits and that it poses lower health risks than other controlled substances.
Recommended
2024 ELECTION
Illinois governor's pro-abortion rights group sinks money into Florida ballot question
2024 ELECTION
Trump on political violence in 2024: 'If we don't win, you know, it depends'
Biden even made history at the State of the Union address this spring, for the first time referencing marijuana from the dais in the House chamber and making note of the federal review process. “No one should be jailed for using or possessing marijuana,” the president said during the speech.
When Biden served as Vice President in former President Barack Obama’s administration, the White House was opposed to any legalization of marijuana because it would “pose significant health and safety risks to all Americans.”
Jim Cole, who served as deputy attorney general in the Obama administration authored the now infamous Cole Memo in 2013 which paved the way for the modern marijuana market. The memo scaled back federal intervention in states that legalized marijuana, as long as they implemented “strong and effective regulatory and enforcement systems to control the cultivation, distribution, sale and possession of marijuana.”
Cole, who is now a member of the National Cannabis Roundtable, told NBC News in an interview this week that reclassifying marijuana to Schedule III would “open up the ability to actually test it and put it in a laboratory without all of the restrictive measures” of a Schedule I drug.
Kevin Sabet, president and CEO of Smart Approaches to Marijuana and a former Obama Administration advisor, said that the decision to reclassify marijuana is "the result of a politicized process," arguing that it "will be devastating for America’s kids, who will be bombarded with attractive advertising and promotion of kid-friendly pot products."
"The only winner here is the marijuana industry, who will receive a new tax break and thus widen their profit margins," said Sabet. “Reclassifying marijuana as a Schedule III drug sends the message that marijuana is less addictive and dangerous now than ever before. In reality, today’s highly potent, super strength marijuana is more addictive and linked with psychosis and other mental illnesses, IQ loss, and other problems.”
Researchers have raised concerns about high-potency marijuana and cannabis-induced psychiatric disorders, particularly young men.
Some challenges ahead
Once the DEA formally makes its announcement, the marijuana industry will see immediate benefit. But with the DEA’s proposed rule change comes a public review period that could lead to a challenge, and perhaps even a change, to the rescheduling proposal.
Once that public comment period has concluded and the Office of Management and Budget reviews the decision, Congress would be also able to overturn the rule under the Congressional Review Act, which gives the legislative branch the power to weigh in on rules issued by federal agencies. Democrats control the Senate with a 51-seat majority and for a CRA to be successful, two-thirds of the House and Senate would be needed to support it, meaning the marijuana rescheduling would likely survive.
Though cannabis remains a divisive topic on Capitol Hill, there has been growing support on a bipartisan basis for marijuana reforms, largely driven by the electorate. Nearly six in ten Americans say that marijuana should be legal for medical and recreational purposes, according to a Pew Research poll last month. Cannabis is legal in 24 states for recreational use.
Congress is considering its own bills
Congress is considering its own measures that would make it easier for legal marijuana businesses to thrive and would allow for more small and minority-owned shops to flood the marketplace.
The SAFER Banking Act, for example, would grant legal marijuana businesses access to traditional banking and financial services and could pass both chambers by the end of the year.
Lawmakers are also considering the HOPE Act, another bipartisan bill that would provide states and local governments resources to automatically expunge criminal records for petty, non-violent cannabis offenses.
There is also a Democratic-only effort to remove cannabis entirely from the Controlled Substances Act, empowering states to create their own cannabis laws and prioritize restorative and economic justice for those impacted by the War on Drugs.
But there is weariness among lawmakers who remember the last time Congress made law surrounding the drug.
The Republican-led Senate legalized hemp production in the 2018 Farm Bill, a decision that led to synthetic and exotic cannabinoids being sold over the counter, oftentimes without regulation, particularly in states where marijuana is not legal.
It’s a gray area that has earned pushback from both sides of the aisle, most recently with the rise of Delta-8: a synthetic THC product that uses chemicals — some of them harmful — to convert hemp-derived CBD into Delta-8 tetrahydrocannabinol.
Stick to talking about PVSP, those two you mentioned don’t belong here since this is a stock specific board, not a general Mary Jane board…
Wrong board? I hold a substantial amount of shares here, guess I have the right to be disappointed?
Some of the Marijuana stocks have been halted.
Complaints of trades not being made!
Oldrogue.
We may see an accelerated Artizen spin out?
Oldrogue.
https://www.marijuanamoment.net/
Finally!
Oldrogue
Rescheduling would eliminate Code 280E, allowing for credits or deductions!!
Were DEA to accept FDA’s current recommendation, it would have significant implications for state-legal cannabis businesses, though the rescheduling would not change the ultimate conflict between state and federal law with respect to the sale and distribution of cannabis and its derivatives.
For example, though rescheduling would not federally legalize these businesses, it would eliminate the burden of Internal Revenue Code 280E (IRC 280E), allowing state-legal cannabis businesses to take credits or deductions other than those for costs of goods sold. Currently, cannabis businesses cannot make these deductions because they are prohibited for businesses that are “trafficking in controlled substances (within the meaning of schedule I and II of the Controlled Substances Act).”
DEA Cannabis Scheduling announcement as early as Today!!!!!
Officials with the nation’s top marijuana prohibitionist advocacy group say they are hearing that the results of the Drug Enforcement Administration’s (DEA) cannabis scheduling review will be announced “very soon,” possibly as soon as “today or tomorrow.”
Marijuana Rescheduling Announcement Coming ‘Very Soon,’ As Early As This Week, Opposition Group Says
Published on April 29, 2024By Kyle Jaeger
Officials with the nation’s top marijuana prohibitionist advocacy group say they are hearing that the results of the Drug Enforcement Administration’s (DEA) cannabis scheduling review will be announced “very soon,” possibly as soon as “today or tomorrow.”
DEA has spent the last eight months considering a U.S. Department of Health and Human Services (HHS) recommendation to move cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA). Now leaders of the organization Smart Approaches to Marijuana (SAM) say they’re seeing indications that DEA’s review is complete and will be revealed imminently.
“We’re hearing a lot of chatter—even as we’re having this podcast, I’m hearing from some sources that pro-marijuana Democratic senators are saying it’s very soon, as in today or tomorrow,” SAM President Kevin Sabet said during an interview on the organization’s “The Drug Report” podcast on Monday. “So it could be wishful thinking or not. I don’t know whether it will be coming as we as we talk. So, again, we’ll see.”
Rumors about the timing of a rescheduling decision have been swirling for months. But the sources of those rumors have been consistently pro-reform, making it all the more notable that this time it’s coming from a prohibitionist group that has advocated for keeping marijuana in Schedule I.
“We are hearing it’s going to come soon. It very well could happen this week,” Sabet said. “But it also could happen in three weeks. It could happen in three months. We don’t know.”
The SAM executive also reiterated his skepticism about the revised Food and Drug Administration (FDA) drug scheduling review process—a talking point that’s also been picked up by certain GOP lawmakers.
“One thing I have to say: Obviously sort of a glass half full-glass half empty way to look at this. Obviously, I don’t like [rescheduling] for many reasons, and we completely oppose it,” Sabet said. “But the glass half full, if you’re going to look at it that way—and I always think you’ve got to sometimes look at it that way, even if it’s overall not good, you don’t want it, you wanted a full glass of water—but if you have a half and you look at it that way, the goalposts have changed.”
Sabet said earlier in the interview that SAM has “some pretty decent intel that [the scheduling review is] moving through the process. There’s no doubt about it.”
He pointed out that past scheduling petitions have taken years to complete, only to have the government deny the asks to reclassify marijuana under the CSA. In this case, however, the scheduling review was directed by President Joe Biden. A DEA official also recently said it sometimes takes up to six months for the agency to complete its analysis of health officials’ recommendations—which is now less than how long it has now been since the agency began its current cannabis assessment.
SAM has long opposed even incremental marijuana reform, and it’s coordinated messaging with GOP lawmakers to discourage DEA from rescheduling marijuana. It’s also encouraged supporters to reach out to their congressional representatives to oppose rescheduling, marijuana banking reform and legalization proposals.
Last week, a coalition of 21 congressional lawmakers told DEA to “promptly remove marijuana from Schedule I,” while recognizing that the agency may be “navigating internal disagreement” on the issue.
That point references reporting in The Wall Street Journal that said DEA officials are “at odds” with the Biden administration over the scheduling review.
Marijuana Moment reached out to DEA about the status of its review multiple times in recent weeks, but representatives have not provided on-the-record comment. The White House has also so far declined to comment about the rumored timeline.
Meanwhile, the head of the Food and Drug Administration (FDA) says there’s “no reason” for DEA to “delay” making a marijuana scheduling decision.
Last month, HHS Secretary Xavier Becerra defended his agency’s rescheduling recommendation during a Senate committee hearing and also told cannabis lobbyist Don Murphy that he should pay DEA a visit and “knock on their door” for answers about the timing of their decision.
You who is waiting to collect the butter from the ant's belly...
You will never fry your eggs 🤣
Many thanks bj ... and also for the news you provide. Keep it coming!
oldroque: yes you’re correct on 3Q, thanks
PVSP fiscal year ends in November, 3 quarter is June, July and August. Check it if you would.
Oldrogue.
IMO Riss will be CEO of PVSP again!!
PVSP is very likely to announce a deal with a private company that wants to go public, just like Artizen did, and Mesa did with HTSC which Riss controlled.
Riss know everything about SEC listing and Spin Offs and is the guy to convince a partner that is seeking to go public that a reverse merger is the cheapest and most efficient way to become a public company and to up list.
The COO has already resigned and is continuing as a consultant which is expected with the spin off of Artizen just weeks away. IMO German will go with Artizen also, these guys know POT that is about it.
Lets see what happens, but Riss is the guy that can get PVSP a new partner with a reverse merger once again.
ccad72 : Page 2 of the filings states spin off of Artizen will be completed in Q3 2024 which is July/August/Sept. Link below:
https://www.otcmarkets.com/otcapi/company/financial-report/398323/content
The DEA must love dragging this along!! We don't care about the benefits and research barriers 🤬🤬
Most folks are realizing the benefits and a lot are seeing it in real time!!
"These changes in state law come as a broad majority of Americans say marijuana should be legal in some way. In an October 2022 Pew Research Center survey, 88% of U.S. adults said the drug should be legal, either for recreational and medical use (59%) or for medical use only (30%). Feb 29, 2024"
https://www.pewresearch.org/short-reads/2024/02/29/most-americans-now-live-in-a-legal-marijuana-state-and-most-have-at-least-one-dispensary-in-their-county/
Congressional Lawmakers Demand DEA ‘Promptly’ Reschedule Marijuana,
Regardless Of ‘Internal Disagreement’ At The Agency
Published on April 25, 2024By Kyle Jaeger
A coalition of 21 congressional lawmakers is telling the Drug Enforcement Administration (DEA) to “promptly remove marijuana from Schedule I,” while recognizing that the agency may be “navigating internal disagreement” on the issue.
In a letter led by Sens. Elizabeth Warren (D-MA) and John Fetterman (D-PA), as well as Reps. Earl Blumenauer (D-OR) and Barbara Lee (D-CA), members told DEA Administrator Anne Milgram and Attorney General Merrick Garland that it’s been eight months since the U.S. Department of Health and Human Services (HHS) recommended that DEA move cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA)—and it’s “time for [DEA] to act.”
They added that the current Schedule I status of marijuana “produces a cascade of severe penalties for marijuana users and businesses, including for criminal records, immigration statuses, employment, taxation, health care, public housing, social services, and more.”
CBD Can Help Treat Pain, Cancer, Schizophrenia, COVID And Other Conditions
Citing prior letters, the lawmakers—including Senate Majority Leader Chuck Schumer (D-NY)—reiterated that while a Schedule III reclassification would be a “meaningful improvement, the only way to remedy the most concerning consequences of marijuana prohibition is to deschedule marijuana altogether.”
“The DEA now has the power to determine whether it will continue the failed approach of keeping marijuana in Schedule I,” the letter says.
“Although some at the DEA have indicated that the agency’s review of an HHS scheduling recommendation often takes up to six months, almost eight months have now passed since the DEA received HHS’s recommendation,” they said. “While we understand that the DEA may be navigating internal disagreement on this matter, it is critical that the agency swiftly correct marijuana’s misguided placement in Schedule I.”
That point references reporting in The Wall Street Journal that said DEA officials are “at odds” with the Biden administration over the scheduling review.
“The longer marijuana remains scheduled in the CSA, the longer our communities face senselessly severe penalties and the longer the marijuana laws of the majority of U.S. states remain in conflict with federal law,” the letter continues. “Right now, the Administration has the opportunity to resolve more than 50 years of failed, racially discriminatory marijuana policy.”
“We trust that the DEA is working as quickly as possible toward a decision on how marijuana is scheduled, as Vice President Kamala Harris recently reassured stakeholders. We are also hopeful that the DEA will not make the unprecedented choice to disagree with HHS’s medical finding that a drug does not belong in Schedule I.”
The letter concludes by applauding President Joe Biden for promoting marijuana reform during his State of the Union address and saying Second Chance Month represents a “prime opportunity to finally begin remedying the harms of marijuana’s scheduling by removing marijuana from Schedule I.”
“We look forward to your prompt action and appreciate your attention to this important matter,” they said.
The letter, which was first reported by HuffPost, also cites a response several senators received from DEA earlier this month explaining that the agency is carrying out its duties in the cannabis review and “must follow the procedures set forth in the [CSA], including an opportunity for a public comment period and a hearing.”
That’s notable, as it appears to be the first time DEA has explicitly acknowledged the likelihood of a public feedback period including a public hearing after it announces the conclusion of its review.
Other signatories on the letter include Senate Finance Committee Chairman Ron Wyden (D-OR), Sens. Bernie Sanders (I-VT), Jeff Merkeley (D-OR), John Hickenlooper (D-CO), Reps. Robert Garcia (D-CA), Dina Titus (D-NV) and more.
Meanwhile, the head of the Food and Drug Administration (FDA) says there’s “no reason” for DEA to “delay” making a marijuana scheduling decision.
Last month, HHS Secretary Xavier Becerra defended his agency’s rescheduling recommendation during a Senate committee hearing and also told cannabis lobbyist Don Murphy that he should pay DEA a visit and “knock on their door” for answers about the timing of their decision.
The way this is going wouldn't surprise me at all!! Zen 😕😕😕
I’m sure the abounding opportunities are those no one else wanted. Not that I care as long as we get to a penny again!!!!
Zen
You don’t need to be seasoned to read a disaster after so many years of no growth. When a Co and it’s most favorable poster always point to ‘gross profit margin’ with no increase in revenue but an increase in net loses, you always know you’re being fed BS. I also like the mention of sales on Oregon with no numbers to support same. Unfortunately, there is NO top marketing management as yet to make this happen while shares are being sold.
Zen
Hey Urocka... I can't seem to find where it states Q3 for the spin-off reschedule! Also... Q3 for this company represents which months? Surely looking like Germany played us for an entire year... despicable!!!
“In the meanwhile, the Company also has entered into negotiations with several parties to bring to Pervasip certain technologies and related opportunities once the spinout is complete.”
Pervasip Announces First Quarter Financial
Reports 2024 First Quarter Revenues of $3.34 Million from Artizen Corporation
April 23, 2024 14:40 ET
| Source: Pervasip Corp.
SEATTLE, WASHINGTON, April 23, 2024 (GLOBE NEWSWIRE) -- Pervasip Corp. (OTCPK: PVSP) (“Pervasip” or the “Company”), a developer of companies and technologies in high value emerging markets, today announced its 2024 first quarter financial results.
Key Highlights
Gross Profit for the quarter ending February 29, 2024 totaled $831,079 on $3,347,086 in revenues, compared to gross profits of $716,213 during the same period in 2023.
Gross Margins increased from 20% to 25%, a 25% increase. The improved gross margin reflects increases in production yields and gains in production efficiencies.
Revenues of $3.34 million decreased slightly from 2023 first quarter revenues of $3.66 million, achieved in a market that continues to battle over supply and price compression.
Operating Loss for the quarter increased to $618,623, deeper than the $501,283 loss reported in the first quarter of 2023. This increase is attributable to one-time expenses related to the restructuring of operational staff and completion of the company’s 2022 audit.
Operating cashflow for the quarter ending February 29, 2024 totaled $98,320 compared to negative cashflow of ($38,044) during the same period in 2023.
Generated first retail sales in Oregon recreational market, fulfilling company’s goal of expanding its retail brand on the West Coast.
The Company initiated its debt and operational restructuring, continuing to reduce low yielding real estate footprint, entering into a voluntary debt restructuring, consolidating operations, and exiting one of its largest facilities which had seen 65% utilization over the past years. With a focus on higher margin products, operational objectives focus on improving gross and operating margins in preparation for the spin out of all of the Company’s cannabis assets.
“We are entering our final phase of restructuring which involves making difficult decisions to ensure additional expense reductions and separating the Company from assets it has held for many years,” said German Burtscher, Pervasip’s president and chief executive officer.
As part of the restructuring, George Jordan has resigned from his duties as CFO and COO of the company and will stay on as an advisor, supporting management through its final phase of changes in preparation of the spin out of Artizen Corporation.
The Company has engaged with Frucci & Associates for the completion of the fiscal 2023 audit of the Company and of Artizen Corporation, which is needed for a spinout and uplisting of Artizen Corporation to OTCQB. In the meanwhile, the Company also has entered into negotiations with several parties to bring to Pervasip certain technologies and related opportunities once the spinout is complete.
The basic and diluted loss per share remained constant at $(0.00), with the weighted average number of shares outstanding increasing slightly to 5,429,231,963 from 5,329,231,963.
As we continue our efforts to streamline operations and focus on higher-margin products, these quarterly figures reflect both the challenges and the ongoing strategic adjustments being undertaken by the company. Our commitment to improving our financial performance remains steadfast as we prepare for the strategic spin-out of Artizen Corporation and engage in new opportunities that align with Pervasip's growth trajectory.
For further information, please contact:
T: 206-590-2408, Extension 102
E: info@pervasip.net
Complete release: https://www.globenewswire.com/en/news-release/2024/04/23/2868067/0/en/Pervasip-Announces-First-Quarter-Financials.html
Man, I'm not seasoned at financial report reading and comprehending all the Details.....that being said things (Numbers) don't look good. Spin-Off schedule now Q3 2024....Dang.....that does Not Rock......Subsequent Events had some disappointing information. A Lot to Absorb....
Bloomberg Marijuana Stocks Gain Momentum on Cannabis Reform Hopes
US Edition
Markets
By Carmen Reinicke
April 19, 2024 at 12:00 PM EDT
Updated on April 19, 2024 at 4:20 PM EDT
Marijuana Stocks Gain Momentum on Cannabis Reform Hopes
Two cannabis funds have beat the S&P 500 in last six months
Investors see major upside for the industry with policy change
Bloomberg
By Carmen Reinicke
April 19, 2024 at 12:00 PM EDT
Updated on April 19, 2024 at 4:20 PM EDT
Investors have been diving into cheap pot stocks in hopes that a change in US policy will unlock major upside for cannabis companies.
A look at funds and stocks following the marijuana industry ahead of the unofficial marijuana holiday of April 20, popularly known a
finally a fact spoken we can all believe -thanks
Long wait but it will be worth it. Next steps
should be announced soon IMO.
Should We Be Getting the late filing Financials Today?? Or Monday??
Need some Numbers!!
Where is the ZEN? $PVSP
Gotcha!! My point was we need some "Showtime" around here!!
My point, ALL of the metals companies in pennyland go nowhere, but most run at least once.
Riss is already in a gold venture - in California and Arizona- it is called agdy
PCAOB Audit completed Feb, Spin Off SOON!!!
Paul Riss
@PaulRiss
·
Feb 9
$PVSP has uploaded PCAOB audited financial statements. Thank you! Thank you! Thank you! Now they can work on #spinoff and creating value. Onward and upward! I think my $MHRE spinoff will happen first. It's a race.
https://twitter.com/PaulRiss
Please explain the relevance to pvsp!! Enlighten us!!!
Zen
I was simply referring to an old post shen he was pumping.
Zen
Schumer And Other Democrats Amplify Calls For Marijuana Reform Ahead Of 4/20
Which Congressman Says Should Be Celebrated ‘Every Day’
Published on April 17, 2024By Kyle Jaeger
Democratic senators, including Senate Majority Leader Chuck Schumer (D-NY), are “trying to recruit Republicans” to join them in the push for federal marijuana legalization, Senate Finance Committee Chairman Ron Wyden (D-OR) said at an event ahead of 4/20, which another lawmaker said is a holiday that should be celebrated “every day” this year as advocates work to get reform “across the finish line.”
At a press briefing organized by the Last Prisoner Project (LPP) on Wednesday, multiple congressional champions of cannabis legalization marked progress in the fight to end prohibition.
As Schumer, Wyden and Sen. Cory Booker (D-NJ) prepare to file a bill to federally legalize marijuana later this month, Wyden said the trio are “out right now trying to recruit Republicans to join in.”
Teen Marijuana Use Has Declined In Washington Since Legalization
“I want you to hear what my message is. I’m gonna say one word: Deschedule,” he said. “Descheduling ought to be a Republican dream… Sometimes I think they’re only for states’ rights if they think the state is right.”
Schumer, meanwhile, applauded advocates and discussed his work on legalization and cannabis banking reform in a pre-recorded video that was shared with Marijuana Moment ahead of a National Cannabis Policy Summit on Wednesday.
“My commitment to ending federal prohibition on cannabis remains as strong as ever,” he said. “As many of you know, cannabis reform is an issue I’ve cared about, and I’ve been working hard on, for years. And as many of you know, momentum is now in our favor.”
“Here in Congress, we’re making some good progress,” he said, pointing to the Senate Banking Committee passage of the Secure and Fair Enforcement Regulation (SAFER) Banking Act last September. Schumer also reiterated his interest in attaching a measure to incentivize state-level cannabis expungements to the legislation when it’s brought to the floor.
The majority leader also talked about his forthcoming Cannabis Administration and Opportunity Act (CAOA) to legalize marijuana.
“Cannabis legalization has proven successful at the state level. It’s high time that Congress catches up with the rest of the country,” Schumer said. “Of course, we know none of this is easy, especially in divided government. We need all of you to continue reaching out to members, especially Republican members, so we can make cannabis reform a reality.”
Back at the LPP event, Congressional Cannabis Caucus founding co-chair Rep. Earl Blumenauer (D-OR) touted his 51 years of work to reform state and federal marijuana laws. He also said it’s “appropriate” that advocates and lawmakers are celebrating 4/20 three days early because, “this year, we ought to be celebrating 4/20 every day.”
“Forces are aligned to be able to end this failed war on drugs and mobilize unprecedented support across the country,” he said. “And, frankly, the Biden administration has been doing a little realignment, which I welcome. But it’s time to not just realign but get it done.”
“President Biden, if I was interested in mobilizing young people—if I was interested in energizing them—this is a no-brainer,” Blumenauer said.
Followers
|
858
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
183590
|
Created
|
10/04/08
|
Type
|
Free
|
Moderators jobynimble DSherman allenc Urocka |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |